iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aarti Drugs Q4FY22 PAT up 7.14% at Rs55.34 crore yoy as EBITDA margins compressed by 351 bps

10 May 2022 , 01:28 AM

Aarti Drugs
Aarti Drugs Ltd reported 38.37% growth in sales revenues yoy for the Q4FY22 quarter on consolidated basis at Rs694.27 crore. On a sequential basis, revenues were higher for the quarter by 9.37%.

For the full year FY22, the revenues were higher by 15.5% at Rs2,489 crore. For Q4FY22, API revenues grew by 46% while API volumes grew by 23%. On a yoy basis, the formulations revenues grew 7.8% while the specialty chemicals revenues grew by 17%.

It expects the growth trajectory of the active pharma ingredients (APIs) to gather momentum in the coming quarters. Exports contributed 39% of the formulation revenues.

The consolidated net profit for Q4FY22 was up 7.14% at Rs55.34 crore while it was down on a sequential basis by -5.06%.

The reason for the fall in profits was the sharp spike in raw material costs. EBITDA for Q4FY22 was up 9.1% at Rs89 crore while EBITDA margins tapered by 351 basis points to 12.8% in the Q4FY22 quarter from 16.35 in the Q4FY21 quarter.

Net margins stood at 7.97% in Q4FY22 quarter compared to 10.29% in Q4FY21. NPM was lower sequentially against 9.18% in Q3FY22. Net cash flows got impacted by spike in receivables.

Financial highlights for Mar-22 compared yoy and sequentially

Aarti Drugs
Rs in Crore Mar-22 Mar-21 YOY Dec-21 QOQ
Total Income (Rs cr) ₹ 694.27 ₹ 501.75 38.37% ₹ 634.80 9.37%
Net Profit (Rs cr) ₹ 55.34 ₹ 51.65 7.14% ₹ 58.29 -5.06%
Diluted EPS (Rs) ₹ 5.97 ₹ 5.54 ₹ 6.29
Net Margins 7.97% 10.29% 9.18%

Related Tags

  • Aarti Drugs management
  • Aarti Drugs news
  • Aarti Drugs Q4
  • Aarti Drugs Q4FY22 PAT
  • Aarti Drugs Q4FY22 Pharma business
  • Aarti Drugs Q4FY22 Result
  • Aarti Drugs quarterly results
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.